Surging Medical Utilization Finally Hitting Cigna's Bottom Line
Cigna has deleveraged substantially after acquiring Express Scripts in late 2018 when Cigna's debt rose to over $42 billion, or debt/capital of 51%. Management has made good progress on its ...
Mizuho maintains neutral on Revance, price target steady at $3.65
Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...